Key Highlights
- Artelo Biosciences (ARTL) shares soared more than 40% during pre-market hours on March 18, 2026
- The spike followed news of a fully-funded clinical trial agreement with Belfast Health and Social Care Trust
- ART27.13, the company’s peripherally selective synthetic cannabinoid, will be evaluated in glaucoma and ocular hypertension patients
- Glaucoma UK and HSC R&D Division are providing complete funding, with initial patient recruitment slated for Q2 2026
- This development arrives shortly after a 1-for-3 reverse stock split executed on March 10, 2026
Shares of Artelo Biosciences (ARTL) experienced a dramatic pre-market rally exceeding 40% on Wednesday following the disclosure of a fully-funded clinical investigation examining its synthetic cannabinoid therapy ART27.13 for glaucoma treatment.
Artelo Biosciences, Inc., ARTL
The investigator-led research initiative was established through a collaboration with Belfast Health and Social Care Trust (BHSCT). Complete financial backing is being supplied by Glaucoma UK alongside the HSC R&D Division.
The research design is structured as a pilot randomized cross-over investigation. Researchers will evaluate ART27.13’s effectiveness in reducing intraocular pressure (IOP) among individuals diagnosed with glaucoma or ocular hypertension.
ART27.13 functions as a peripherally selective synthetic cannabinoid receptor agonist. This mechanism allows it to activate cannabinoid receptors located in peripheral tissue regions — such as ocular structures — while avoiding central nervous system interaction.
Current glaucoma management relies predominantly on topical eye drop formulations, which frequently encounter challenges with patient compliance and sustained therapeutic benefits. According to Artelo, ART27.13’s unique formulation may circumvent the psychoactive adverse effects that have historically constrained cannabinoid-derived ophthalmologic therapies.
The investigation protocol has secured clearance from an ethics review board and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). Initial patient recruitment is anticipated to commence during Q2 2026.
Professor Augusto Azuara-Blanco will serve as principal investigator. He holds a position as clinical professor of ophthalmology at Queen’s University Belfast and maintains recognized expertise in glaucoma clinical research.
Glaucoma impacts over 80 million individuals globally and represents a primary cause of permanent vision loss. Increased IOP remains the principal modifiable risk element in disease advancement.
Capital-Conscious Development Approach
CEO Greg Gorgas characterized the partnership as aligned with the company’s resource-efficient development methodology. The organization is enabling external sponsors to conduct this investigation while maintaining internal resources focused on ART27.13’s core indication — cancer-associated anorexia.
“This collaboration exemplifies our capital-efficient development strategy,” Gorgas said in the announcement. “Each study contributes to a growing body of evidence that could enhance the value of ART27.13.”
Under the partnership terms, Artelo will provide ART27.13 capsules serving as the Investigational Medicinal Product for the research. All other financial responsibilities remain with the study’s external sponsors.
Current Financial Position
The pre-market rally unfolds amid difficult financial circumstances. Artelo disclosed a net operating loss of $12.9 million for the fiscal period ending December 31, 2025, representing an increase from the prior year’s $9.8 million deficit.
Cash reserves and investment holdings totaled merely $0.6 million at that reporting date. InvestingPro’s Financial Health Score designates the company as “WEAK.”
On March 10, 2026, the firm executed a 1-for-3 reverse stock split. Common shares outstanding decreased from approximately 2.1 million to 708,323 shares following the consolidation.
Before Wednesday’s movement, ARTL had experienced a 67% decline during the preceding six-month period. The stock was valued at $4.85 with a market capitalization of approximately $3.47 million ahead of the pre-market surge.
The glaucoma investigation marks Artelo’s initial entry into ophthalmologic applications and its first externally-sponsored clinical research arrangement.
